Roche: FDA accepts sBLA for subcutaneous Lunsumio VELO plus Polivy in relapsed/refractory LBCL

Regulatory update

The US Food and Drug Administration has accepted Roche’s supplemental Biologics License Application for subcutaneous Lunsumio VELO (mosunetuzumab) in combination with Polivy (polatuzumab vedotin) to treat adult patients with relapsed or refractory large B‑cell lymphoma (LBCL), including diffuse large B‑cell lymphoma, after at least one prior systemic therapy. The FDA target action date is 9 February 2027.

Phase III SUNMO results

Acceptance is based on the SUNMO trial, a randomised, open‑label phase III study in transplant‑ineligible patients. At a median follow‑up of 23.2 months, the Lunsumio VELO plus Polivy arm reduced the risk of disease progression or death by 59% versus rituximab, gemcitabine and oxaliplatin (R‑GemOx) (HR 0.41; 95% CI 0.28–0.61; p<0.0001), with median progression‑free survival of 11.5 months versus 3.8 months for R‑GemOx.

Safety and follow‑up

The combination’s safety profile was consistent with known profiles of the individual agents. Cytokine release syndrome (CRS) occurred in roughly one in four patients, with fewer than 5% experiencing Grade 2 or 3 CRS. Updated data presented at major oncology meetings showed continued PFS benefit, notably in the second‑line setting, with no new safety signals.

Clinical context and access implications

LBCL is the most common non‑Hodgkin lymphoma and up to 40% of patients relapse or are refractory after frontline therapy. The submission positions a chemotherapy‑free, outpatient‑ready regimen that—if approved—could expand access in community settings where most US patients receive care and reduce logistical barriers associated with inpatient or highly specialised therapies.